SANTA BARBARA, CA—May 28, 2025—Mike Robinson, founder of the Global Cannabinoid Research Center and CEO of Nanobles Corporation, has been appointed to the organizing committee of the 3rd International Cancer and Breast Cancer Treatment Conference. The event will take place November 3–4, 2025, at the City Seasons Hotel in Dubai, UAE.
Pioneering Endocannabinoid Science in Oncology
Robinson brings over two decades of experience in plant-based and endocannabinoid-focused therapies. His work began during his own battles with multiple cancers. While undergoing treatment, he pioneered cannabinoid- and endocannabinoid-based strategies to support immune balance and tissue regeneration. His ongoing research programs include:
-
Nano® Skin and Hair: formulations to support tissue regeneration
-
GENEVEX®: a targeted therapy for tumor-related pain relief
-
Thermonoids®: endocannabinoid-based homeostasis and inflammation control
-
Indole-A™: indole alkaloid compounds to boost cellular defense
-
PREVENT®: an enzyme therapy for cancer prevention and early intervention
In February 2025, after years of care at the Santa Barbara Cancer Treatment Center and UCLA, Robinson was declared in complete remission. UCLA confirmed that both his non-Hodgkin lymphoma, first diagnosed in 2003, and a second cancer were no longer detectable.
Committee Role and Conference Themes
As an organizing committee member, Robinson will:
Guide the scientific program and agenda
Curate and evaluate research abstracts
Foster international collaboration among oncologists, immunologists, and cannabinoid experts
Highlight integrative and emerging therapies for cancer and breast cancer treatment
The conference, themed “The Latest Revolution in Cancer and Breast Cancer Treatment: Advancing Medicine and Hope,” will feature keynote speeches, workshops, interactive panels, and poster sessions. Attendees may participate in person or virtually.
Advancing Integrative Cancer Care
“I am honored to join this global effort and to work alongside leading experts,” Robinson said. “Cannabinoid science offers new possibilities in palliative and adjunctive cancer care. This conference will help bridge the gap between cutting-edge research and compassionate treatment.”
David Uhalley, COO of Nanobles Corporation, added, “Mike’s pioneering work—especially with therapies like PREVENT®—is reshaping how we view cancer prevention and support. His role on the committee will ensure that the endocannabinoid system receives the attention it deserves in modern oncology.”
About Mike Robinson
Mike Robinson is founder and CEO of Nanobles Corporation and the Global Cannabinoid Research Center. He has led international workshops and published research on ECS-based therapies. His unique perspective blends traditional oncology with botanical and endocannabinoid medicine.
About the Conference
The 3rd International Cancer and Breast Cancer Treatment Conference convenes leading healthcare professionals, researchers, and patient advocates to discuss innovations in cancer therapy. The event will be held November 3–4, 2025, at City Seasons Hotel, Dubai, UAE.
Related topics:
- Lily Allen Shares First Breast Augmentation Photo Post-David Harbour Split
- Charity Gets £25k To Support Women With Breast Cancer
- India’s First Robot-Assisted Heart, Breast Surgery In Delhi
